Business
8th Annual Bio Investor Forum
8th Annual Bio Investor Forum.
About this update from Immupharma Plc
[{"type":"text","content":"\n RNS Number : 3723Z Immupharma PLC 21 September 2009 \n \n\n\n\n\n\n\n\n\nFor Immediate Release\n\n\n21 September 2009\n\n\n\n\n\n\n\nImmuPharma PLC\n\nIMMUPHARMA TO PRESENT AT 8TH ANNUAL BIO INVESTOR FORUM\n\nImmuPharma PLC (LSE:IMM), the drug discovery and development group announces that Dimitri Dimitriou, Chief Executive Officer will be presenting at the 2009 BIO Investor Forum. Hosted by the Biotechnology Industry Organisation (BIO), the 8th Annual BIO Investor Forum will take place on October 28-29 at the Palace Hotel in San Francisco, California. \n\n- Ends -\n\nFor further information please contact: \n\n\n\n\n\nImmuPharma PLC:\n\n\n+44 20 7152 4080\n\n\n\n\nDimitri Dimitriou, Chief Executive Officer \n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nBuchanan Communications:\n\n\n+44 20 7466 5000\n\n\n\n\nLisa Baderoon \n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nNotes to Editors\n\nAbout ImmuPharma PLC\n\nImmuPharma is a drug discovery and development group with its key operations in London and subsidiaries in Mulhouse, France and Basle, Switzerland. The Company aims to develop novel drugs to treat serious medical conditions for which there is a high unmet need. It has five drugs in development to treat 1) Lupus, 2) Cancer, 3) Severe Pain, 4) Highly resistant infections like MRSA and 5) Inflammatory and Allergic disorders. \n\nIts lead candidate for the treatment of Lupus, LupuzorTM, a chronic, life-threatening autoimmune disease, was licensed to Cephalon, Inc in a transaction worth up to $500m in milestone payments in addition to significant royalties. $45m in cash has been received to date - $15m in Q4 2008 and $30m post year end in Q1 2009\nThe company also has a strong proprietary and collaborative drug development pipeline.\n\nAbout The Bio Investor Forum \n\nThe 8th Annual BIO Investor Forum is an international conference featuring late-stage private and emerging public companies. This year's BIO Investor Forum will feature more than 110 presentations by private and publicly traded companies, venture philanthropy organizations, and patient advocacy groups; as well as Therapeutic Workshops™ and Business Roundtables with distinguished clinicians, investigators, and investors. Experts hand-selected to speak a...